Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07635524 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.
A Phase 2 study, sponsored by Hoag Memorial Hospital Presbyterian.
- Not yet
- Registry status
- Phase 2
- Development phase
- 34
- Enrollment target
NCT07635524 is a Phase 2 study that has not yet begun recruiting, run by Hoag Memorial Hospital Presbyterian. The registered enrollment target is 34 participants.
The verdict
NCT07635524, a Phase 2 study, has not yet begun recruiting, sponsored by Hoag Memorial Hospital Presbyterian.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 34 participants
- Enrollment target
Study Summary
The purpose of this research is to test whether a new investigational Molecular Imaging (MI) agent called 61Cu-NU101 is equal to or better than a currently used MI agent, Pylarify, for the detection of prostate cancer metastases. 34 participants with biopsy-proven prostate cancer and cancer seen on a Pylarify PET scan will be enrolled in this study. The investigational 61Cu-NU101 PET/CT will be perfromed. If there is a difference between the standard Pylarify exam and the investigational 61Cu-NU101 exam, a biopsy of one lesion that is different between the two exams may be performed.
Interventions
- DRUG Cu-NU101
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2026-08-01 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07635524
The ClinicalTrials.gov registry entry for NCT07635524 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hoag Memorial Hospital Presbyterian, which has 20 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cu-NU101 is the first listed.
NCT07635524 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07635524 about?
NCT07635524 is a clinical study titled "A Phase 2 Trial of 61Cu-NU101 PET/CT Compared Against Current Standard-of-care 18F-piflufolastat (Pylarify®) PET/CT.". The purpose of this research is to test whether a new investigational Molecular Imaging (MI) agent called 61Cu-NU101 is equal to or better than a currently used MI agent, Pylarify, for the detection of prostate cancer metastases. 34 participants with biopsy-proven prostate cancer and cancer seen on...
What is the current status of trial NCT07635524?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 34 participants. The study started on 2026-08-01. Estimated completion is 2028-10-01.
What interventions are being tested in trial NCT07635524?
The interventions under investigation include: Cu-NU101 (DRUG).
Who is sponsoring clinical trial NCT07635524?
This trial is sponsored by Hoag Memorial Hospital Presbyterian, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.